Home > Healthcare > Pharmaceuticals > Disease Specific Drugs > Phenylketonuria (PKU) Treatment Market

Phenylketonuria (PKU) Treatment Market Share

Report ID: GMI11037
Published Date: Aug 2024
Report Format: PDF

Download Free Sample

Phenylketonuria Treatment Market Share

The market is witnessing significant competition among major contributing to advancements in treatment technologies. These companies are actively investing in research and development to enhance PKU treatment platforms, forming strategic partnerships and acquisitions to broaden their market presence, and collaborating with healthcare providers and academic institutions to drive innovation. Such strategic initiatives are pivotal in capturing market share and addressing the growing demand for effective PKU treatments, thereby shaping the competitive landscape of the industry.

Phenylketonuria Treatment Market Companies

Few of the prominent players operating in the PKU treatment industry include both products available in market as well as in clinical development:

Abbott Laboratories
American Gene Technologies
APR Applied Pharma Research s.a.
BioMarin Pharmaceutical Inc.
Codexis, Inc.
Erytech Pharma SA
Homology Medicines, Inc.
Lysogene S.A.
PIAM Farmaceutici S.P.A.
Pluvia AS
PTC Therapeutics
SOM Innovation Biotech SL
Synlogic
Ultragenyx (Dimension Therapeutics)
Vitaflo International Ltd.

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

The phenylketonuria treatment industry was valued at USD 737.7 million in 2023 and is anticipated to register a 7.2% CAGR between 2024 and 2032 augmented by the rising incidence of PKU globally and advancements in treatment options.

The classic PKU segment will showcase a 7% CAGR over 2024-2032, because of its high prevalence and the well-established need for lifelong management.

The U.S. PKU treatment market size is anticipated to reach USD 502.5 million by 2032, thrusted by advancements in diagnostic and treatment technologies.

Abbott Laboratories, American Gene Technologies, APR Applied Pharma Research s.a., BioMarin Pharmaceutical Inc., and Codexis, Inc., among others.